– USA, PA – Vensun Pharmaceuticals, a privately held generic pharmaceutical company, today announced that Ed Schutter has joined its Board of Directors. Mr. Schutter is a seasoned executive with over 30 years of experience in the pharmaceutical industry. Mr. Schutter is currently President and Chief Executive Officer of Arbor Pharmaceuticals, a specialty pharmaceutical company focused on the cardiovascular, hospital, and pediatric markets as well as generics through its Wilshire division. He also serves on the board of directors at Arbor.
“Ed brings a tremendous wealth of commercial and operational experience to the Board. His perspective and insights will be valuable as Vensun continues to transition from a research and development organization to a sales and marketing entity”, said Hem Pandya, President & CEO of Vensun Pharmaceuticals. “In addition to his extensive commercial experience, Ed has been instrumental in driving growth with a proven track record of building successful specialty pharmaceutical companies.”
“I believe Vensun has established a very strong foundation with its impressive research and development portfolio, setting a clear path for sustainable growth and value creation. I am extremely excited to join the Board and help contribute to Vensun’s growth”, commented Mr. Schutter.
Prior to joining Arbor, Mr. Schutter served as President and Chief Operating Officer of Sciele (Shionogi) Pharmaceuticals. Prior to Sciele, he served as VP of Global Business Development at Solvay Pharmaceuticals based in Basel, Switzerland. Mr. Schutter also held several senior management roles in commercial operations at the U.S. subsidiary of Solvay during his twenty years with the organization. He began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, Ga. Mr. Schutter has a BS in Pharmacy from Mercer University and an MBA from Kennesaw State University.
About Vensun Pharmaceuticals, Inc.
Vensun Pharmaceuticals, Inc., based in Yardley, Pennsylvania, is a rapidly emerging generic pharmaceutical company, established in July 2011. The company is developing a unique portfolio of complex generic prescription products in various dosage forms covering a broad range of therapeutic categories. Vensun is developing products in collaboration with a number of strategic partners in the US and overseas and has filed 20 ANDAs to date and has 15 products in active development. In addition to this proprietary product development program, Vensun has also in-licensed 23 products to expand and diversify the pipeline.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.